Table 1. Patient characteristicsa

PatientsPrimary Renal DiseaseDuration of α-IFN Therapy (mo)Liver Biopsy before Treatment (Total Knodell/Metavir Scores)Time Since End of α-IFN Therapy and RT (mo)HLA A/B/DR MatchingInduction TherapyImmunosuppressive Treatment
3 mo after RTLast Follow-up
a Abbreviations: RT, renal transplantation; NA, not available; CIN, chronic interstitial nephropathy; CGN, chronic glomerulonephritis; MGN, membranous glomerulonephritis; ATG, antithymocyte globulins; ALG, antilymphocyte globulins; CsA, cyclosporin A; MMF, mycophenolate mofetil; AZA, azathioprin; C, corticosteroids; FK506, tacrolimus; SRL, sirolimus.
1Polycystic renal disease6NA561A/1BATGCsA/MMF/CCsA/MMF/C
2Henoch-Schölein purpura63/A1F0311B/1DRATGCsA/MMF/CCsA/MMF/C
3NA121/A0F1361A/1DRATGCsA/MMF/CCsA/MMF/C
4CIN12NA61B/1DRFK506/MMFFK506/MMF
5CGN125/A1F1171A/1B/1DRATGCsA/AZA/CCsA/MMF/C
6Polycystic renal disease12NA572A/1B/2DRATGCsA/MMF/CCsA/MMF/C
7Malformative uropathy121/A0F0421A/2B/1DRAnti-IL2RCsA/MMF/CSRL/MMF/C
8IgA nephropathy12NA22A/1BFK506/MMF/CFK506/MMF/C
9CGN123/A0F1112DRATGCsA/AZA/CCsA/AZA/C
10Henoch-Schölein purpura125/A1F0451A/1B/1DRATGFK506/MMF/CSRL/MMF/C
11Malformative uropathy64/A1F0451A/1DRATGCsA/AZA/CCsA/MMF/C
12Diffuse crescentic glomerulonephritis128/A2F2402DRAnti-IL2RCsA/MMF/CCsA/MMF
13Malformative uropathy124/A1F1441A/1B/2DRATGCsA/MMF/CCsA/MMF/C
14NA124/A1F1382A/2B/2DRATGCsA/MMF/CCsA/MMF/C
15Fanconi’s syndrome127/A2F231.52A/2B/1DRATGCsA/MMF/CCsA/MMF/C
16MGN12NA51B/1DRALGCsA/MMF/CCsA/MMF